Bridging Therapy in Patients at High Risk for Stent Thrombosis Undergoing Surgery

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2009 by Cedars-Sinai Medical Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Cedars-Sinai Medical Center
ClinicalTrials.gov Identifier:
NCT00653601
First received: April 2, 2008
Last updated: September 3, 2009
Last verified: September 2009

April 2, 2008
September 3, 2009
April 2008
April 2011   (final data collection date for primary outcome measure)
In-stent thrombosis as assessed by acute coronary syndromes of unstable angina/non-ST elevation myocardial infarction or ST-elevation myocardial infarction during the hospitalization. [ Time Frame: until discharge ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00653601 on ClinicalTrials.gov Archive Site
  • Platelet function using the Verify Now device: T1 - at admission (2-3 days after the D/C of Plavix and prior to initiation of Aggrastat infusion); T2 - > 8 hours after initiation of Aggrastat; T3 - pre-operative; T4 - post loading dose of clopidogrel. [ Time Frame: until discharge ] [ Designated as safety issue: Yes ]
  • Bleeding as assessed by hematocrit values obtained immediately pre-operative, immediately post-operative, and prior to discharge In addition, the use of blood products (pRBCs, platelets, FFP) will be assessed. [ Time Frame: until discharge ] [ Designated as safety issue: Yes ]
Platelet function using the Verify Now device: T1 - at admission (2-3 days after the D/C of Plavix and prior to initiation of Aggrastat infusion); T2 - 8 hours after initiation of Aggrastat; T3 - pre-operative; T4 - post-operative (12hrs). [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Bridging Therapy in Patients at High Risk for Stent Thrombosis Undergoing Surgery
Bridging Therapy in Patients at High Risk for Stent Thrombosis Undergoing Surgery

Patients who have undergone placement of coronary stents require dual antiplatelet therapy with Plavix and aspirin to prevent the serious complication of in-stent thrombosis. Some of these patients will require surgery while on dual antiplatelet therapy. This poses a challenge because being on Plavix is associated with higher risks of perioperative bleeding, but stopping Plavix puts patients at increased risk for in-stent thrombosis.

Currently, the ACC/AHA guidelines recommend discontinuation of Plavix five days prior to surgery to prevent bleeding complications. However, there are no universal recommendations for preventing in-stent thrombosis. Some experts recommend the use glycoprotein IIb/IIIa inhibitors (short-acting antiplatelet agents) as "bridging therapy" during the high-risk perioperative period. Although these agents should be beneficial based on theory, there is currently no published data on their effectiveness for this purpose.

The current study proposes to evaluate the value of Aggrastat (a short-acting intravenous platelet glycoprotein IIb/IIIa inhibitor) in decreasing the risk of in-stent thrombosis without increasing the risk of perioperative bleeding.

A. D/C clopidogrel 5 days prior to surgery

B. Continue ASA (Increase dose to 325 mg until prohibitive bleeding risk)

C. Check baseline IIb/IIIa and P2Y12 via the Verify Now device prior to initiating tirofiban

D. Start Tirofiban 2 days prior to the procedure (Patient MUST be on a monitored bed)

  • Load Tirofiban ONLY if P2Y12 (Verify Now Assay) platelet inhibition is < 20% OTHERWISE initiate only the continuous infusion dose
  • Creatinine clearance > 30mL/min: Tirofiban 0.4 mcg/kg/min for 30 minutes, followed by continuous infusion at 0.1 mcg/kg/min
  • Creatinine clearance < 30mL/min: Tirofiban 0.2 mcg/kg/min for 30 minutes, followed by continuous infusion of 0.05 mcg/kg/min

E. Check steady state IIb/IIIa inhibitor verify now assay (>8 hour after initiation)

F. Hold Tirofiban 12 hours prior to procedure

G. Check IIb/IIIa inhibitor verify now assay (10-12 hours after Tirofiban is discontinued)

H. CBC pre and post op

I. Reload clopidogrel> 24 hours post op (300 mg X 1 then 75 mg daily) unless prohibitive bleeding risk

J. Reduce ASA to pre-procedure dose. Restart ASA, 24 hours port-op if it was D/C prior to procedure

K. Check P2Y12 via the Verify Now device post-loading dose of clopidogrel (test cannot be performed w/in 48 hours of the D/C of IIb/IIIa inhibitor (tirofiban)

Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

2 mL of blood for testing X 5 per patient

Non-Probability Sample

Patients' with BMS/DES on plavix prior to surgery who are in need of an elective procedures

  • Bleeding
  • Thrombosis
Not Provided
  • 1
    Patients who receive bridge therapy with tirofiban who were previously on plavix for drug eluting or bare metal stent prior to scheduled invasive procedures
  • 2

    Patients who do NOT receive bridge therapy previously on plavix for drug eluting or bare metal stent prior to scheduled invasive procedures. This will entail of a matching case-control for the following characteristics.

    • # of RF for stent thrombosis
    • types of stents
    • time frame when the stents were placed
    • procedure type
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
20
April 2011
April 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients' with BMS/DES on plavix prior to surgery who are in need of an elective procedures

Exclusion Criteria:

  • Patients' with BMS/DES on NOT plavix prior to surgery who are in need of an elective procedures
Both
18 Years and older
No
Not Provided
United States
 
NCT00653601
Pro00014008
No
Dr Sanjay Kaul, PI, CSMC
Cedars-Sinai Medical Center
Not Provided
Principal Investigator: Sanjay Kaul, MD Attending physician
Cedars-Sinai Medical Center
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP